Improving therapy for NUT carcinoma using a genetically engineered mouse model
Official title: Genetically engineered mouse model to improve therapy of NUT carcinoma
Funded at Brigham and Women's Hospital · NIH-10931673 · Data updated 2026-11-12
This study is looking at a tough type of cancer called NUT carcinoma to find better ways to treat it, using specially designed mice to see how the cancer grows and how we might stop it with new medicines.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 19, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $629,248 |
| NIH project number | 5R01CA285308-02 |
| Project ID | NIH-10931673 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with NUT carcinoma, regardless of age.
✕Less likely to help
Patients with other types of cancer or those not diagnosed with NUT carcinoma may not benefit from this research.
What this research studies
This research focuses on NUT carcinoma, a highly aggressive cancer with limited treatment options and a very low survival rate. The team has developed a genetically engineered mouse model to better understand the mechanisms driving this cancer and to identify potential therapeutic targets. By studying how tumor cells interact with their environment, the researchers aim to discover new ways to inhibit cancer growth using specific small molecules known as BET bromodomain inhibitors. This approach could lead to more effective treatments for patients suffering from this lethal disease.
Why it matters
Potential benefit: If successful, this research could lead to improved survival rates and treatment options for patients with NUT carcinoma.
How similar studies have gone: Previous research has shown promise in using BET inhibitors for treating cancers driven by similar mechanisms, indicating potential for success in this novel approach.
Where this research is happening
-
Brigham and Women's Hospital
Boston, United States Active
Researchers
- Principal investigator: French, Christopher a — Brigham and Women's Hospital
- Study coordinator: French, Christopher a
Related research
Other NIH-funded projects on the same topics.
-
Novel idea: Epstein-Barr virus and eye cancer in people living with HIV in Zimbabwe
A study explores whether Epstein-Barr virus could cause a type of eye cancer in people living with HIV in Zimbabwe.
-
Glutamine and macrophage behavior in liver cancer
A funded project at a medical university aims to understand how the liver’s immune cells interact with a specific type of liver cancer by looking at metabolism, especially glutamine and ammonia.
-
Understanding bladder cancer biology to find new biomarkers and therapies
A study at Tuskegee University will look at the molecules inside high-grade bladder cancer to discover new markers and potential treatment targets.
-
Oral cancer recurrence predictor using tumor microbes and gene activity
This NIH grant explores how bacteria and immune signals inside oral cancer tumors relate to whether the cancer comes back, with the aim of making a practical risk predictor for patients.
-
Understanding how bladder cancer starts in Veterans exposed to carcinogens and the role of PPAR-g in early bladder cancer
A research team is studying how bladder cancer begins and progresses in Veterans exposed to carcinogens, focusing on the PPAR-γ protein and early precancerous changes.
-
Adding PSMA PET/CT imaging to liver cancer care for veterans
This project tests a new PET imaging approach to help diagnose and guide treatment for liver cancer in veterans.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.